These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Association between clinicopathologic characteristics and BRAF Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596 [TBL] [Abstract][Full Text] [Related]
7. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan. Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047 [TBL] [Abstract][Full Text] [Related]
8. High Prevalence of Liu X; Zhang Y; Zhou CX Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679 [TBL] [Abstract][Full Text] [Related]
9. BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy. Wang CJ; Zhu T; Zhao CZ; Cui H; Wang D; Zhao ZJ; Huang XT; Li HL; Liu FF; Zhang R; Li ZG; Cui L Pediatr Blood Cancer; 2024 Sep; 71(9):e31099. PubMed ID: 38845144 [TBL] [Abstract][Full Text] [Related]
10. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505 [TBL] [Abstract][Full Text] [Related]
11. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688 [TBL] [Abstract][Full Text] [Related]
12. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival. Bhatia P; Singh M; Sharma M; Sharma A; Kakkar N; Radhika S; Trehan A; Bansal D Blood Cells Mol Dis; 2020 May; 82():102356. PubMed ID: 32171112 [TBL] [Abstract][Full Text] [Related]
13. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis. Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356 [TBL] [Abstract][Full Text] [Related]
17. Detection of BRAF V600E mutation in radiological Langerhans cell histiocytosis-associated neurodegenerative disease using droplet digital PCR analysis. Shimizu S; Sakamoto K; Kudo K; Morimoto A; Shioda Y Int J Hematol; 2023 Jul; 118(1):119-124. PubMed ID: 37010809 [TBL] [Abstract][Full Text] [Related]
18. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167 [TBL] [Abstract][Full Text] [Related]
19. [Status of Langerhans cell histiocytosis in children and adults]. Kudo K Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857 [TBL] [Abstract][Full Text] [Related]
20. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment. Kobayashi M; Tojo A Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]